WorksheetsDRUGS FOR ALZHIEMER’S AND PARKINSON’S DISEASES
Total questions: 10
Worksheet time: 20mins
Which of the following statements best explains why carbidopa enhances the action of levodopa in Parkinson’s disease?
A. Carbidopa inhibits dopamine reuptake in the CNS
B. Carbidopa blocks peripheral metabolism of levodopa by inhibiting COMT
C. Carbidopa prevents decarboxylation of levodopa in peripheral tissues
D. Carbidopa increases CNS dopamine receptor sensitivity
A patient with Parkinson’s disease on levodopa monotherapy develops worsening motor symptoms after starting a new vitamin supplement. Which component of the supplement most likely caused loss of levodopa efficacy?
Vitamin B6
Vitamin B12
Vitamin C
Vitamin D
Which adverse effect is most characteristic of amantadine therapy in Parkinson’s disease?
Acute hepatic necrosis
Livedo reticularis
Cholestatic jaundice
Elevated liver transaminases
A 65-year-old patient on long-term levodopa therapy presents with involuntary facial grimacing and tongue thrusting. Which of the following best explains this adverse effect?
Dopamine receptor blockade in the basal ganglia
Excess dopamine activity in the striatum
Destruction of cholinergic neurons
Peripheral dopamine receptor overstimulation
Which of the following agents acts as a D2 receptor agonist but is a partial agonist/antagonist at D1 receptors?
Pramipexole
Bromocriptine
Ropinirole
Entacapone
Which statement best describes the mechanism of rivastigmine in Alzheimer’s disease?
Selective inhibition of peripheral AChE
Reversible inhibition of only BuChE
Dual inhibition of AChE and BuChE in the brain
Direct agonist at muscarinic receptors
Which drug used in Alzheimer’s disease can also exert direct agonistic action on nicotinic receptors, enhancing cholinergic neurotransmission?
Galantamine
Tacrine
Rivastigmine
Donepezil
A patient with severe Alzheimer’s disease is started on donepezil. Which pharmacokinetic feature most contributes to its once-daily dosing?
Extensive first-pass metabolism
Low volume of distribution
Very long elimination half-life
Slow GI absorption
Which of the following is true regarding entacapone use in Parkinson’s disease?
It inhibits peripheral COMT, prolonging levodopa action
It prevents central dopamine degradation
It is effective as monotherapy in early PD
It causes hypertensive crisis with levodopa
A clinician wants to prescribe an Alzheimer’s medication that has minimal peripheral cholinergic side effects because the patient has a history of chronic bradycardia and diarrhoea. Which drug BEST fits this requirement?
Donepezil
Galantamine
Tacrine
Memantine
